Exelixis, Inc. — Form 10-Q Summary
Period discrepancy: The request identifies 2018 Q3, but the supplied filing is for the quarter ended September 27, 2019 (reported as September 30, 2019), with comparisons to 2018. This summary covers the filing provided.
Business context and reporting period
Exelixis is an oncology-focused biotechnology company. Its principal commercial product is CABOMETYX (cabozantinib), alongside COMETRIQ; it also receives collaboration revenue from partners. The filing reports the three and nine months ended September 30, 2019.
Financial performance and position
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Total revenue | $271.7M | $225.4M | $727.5M | $625.2M |
| Net product revenue | $191.8M | $162.9M | $565.0M | $443.1M |
| Operating income | $115.6M | $125.2M | $292.2M | $327.3M |
| Net income | $97.5M | $126.6M | $252.3M | $330.0M |
| Diluted EPS | $0.31 | $0.41 | $0.80 | $1.05 |
| Operating cash flow | Not separately provided | Not separately provided | $368.9M | $311.1M |
- Q3 revenue increased 21%; CABOMETYX product revenue rose 18% to $187.4M. Nine-month total revenue increased 16%, while net product revenue rose 28%.
- Q3 operating margin was approximately 42.5%, versus 55.5% a year earlier; gross margin was reported at 96% in both periods. Net income declined despite revenue growth, primarily amid higher R&D expense and income taxes.
- Q3 R&D expense increased 117% to $97.3M; nine-month R&D expense increased 94% to $242.5M. SG&A rose 7% in Q3 to $51.3M.
- At September 30, cash and investments totaled $1.248B; cash and cash equivalents were $242.3M. Total assets were $1.785B and total liabilities $181.1M. The balance sheet shows no borrowing debt; lease liabilities totaled $26.5M.
- Nine-month investing activities used $457.0M, mainly reflecting purchases of investments. Cash, cash equivalents and restricted cash decreased $72.6M over the period.
Material changes versus prior comparable period
- Revenue growth was driven by CABOMETYX sales, higher royalty revenue from Ipsen, and collaboration milestones. Q3 included a $50M Ipsen commercial milestone; nine-month revenue also included milestones from Daiichi Sankyo and Takeda.
- Collaboration revenue rose 28% in Q3 but declined 11% for the first nine months, reflecting the timing and amount of milestones. Collaboration revenue can vary substantially between periods.
- Higher R&D reflected expanded cabozantinib trials and new Iconic and Aurigene arrangements. R&D costs included $20.5M more license and collaboration costs in Q3 than in Q3 2018.
- The effective tax rate rose to 20.5% in Q3 and 19.4% for nine months, compared with 1.8% and 1.7%, respectively, in 2018. Exelixis had released substantially all of its deferred-tax-asset valuation allowance at year-end 2018.
Outlook, risks and unusual items
- No specific full-year revenue or earnings guidance is provided. Management said available resources and expected product and collaboration revenue should fund operations for at least 12 months after filing.
- Management expects R&D expense to continue increasing as cabozantinib trials and pipeline investment expand, and SG&A to increase modestly. It expected gross margin to remain broadly stable and product discounts and allowances, as a percentage of gross sales, to increase during the rest of 2019.
- Key clinical programs include CheckMate 9ER, COSMIC-311, COSMIC-312 and COSMIC-313; the filing reported that top-line CheckMate 9ER results were expected in early 2020. Trial outcomes, regulatory decisions and partner execution remain uncertain.
- Commercial performance depends heavily on CABOMETYX, payer coverage and reimbursement, competition (including immunotherapy combinations), and collaborators Ipsen and Takeda. Failure to sustain product sales or obtain expected milestones could pressure funding and operating plans.
- In October 2019, Exelixis sued MSN Pharmaceuticals over its generic CABOMETYX application, seeking to enforce a patent expiring October 8, 2030. The company cautioned that litigation may not prevent generic entry; its composition-of-matter patent expires in 2026.
- Subsequent lease commitments are notable: an October 2019 build-to-suit lease for approximately 220,000 square feet, with estimated monthly base rent of about $726,000 and a 242-month term, subject to development conditions; a separate planned expansion of existing premises would extend the lease through 2031. These commitments were not reflected in September 30 lease balances.
Most important facts for investors to verify
- Confirm the intended reporting period: the request says 2018 Q3, but the supplied filing is 2019 Q3.
- Assess how much revenue and cash generation depend on CABOMETYX sales, milestone timing, and Ipsen/Takeda royalties and collaboration activity.
- Review the drivers, expected duration and funding implications of the sharp increase in R&D spending and the clinical programs underway.
- Track CABOMETYX competitive performance, payer access, discounts and rebates, and developments in the MSN patent litigation and generic-entry timeline.
- Evaluate the full cost and accounting impact of the new and amended leases, including operating expenses, tenant improvements and contingent commencement conditions.